newsletter masthead
October 5, 2018
National Cancer Institute's Fiscal Year 2020 Annual Plan and Budget Proposal
NCI 2020 Budget Plan The National Cancer Institute recently released 
its Fiscal Year 2020 Annual Plan and Budget Proposal. The plan highlights the four key focus areas identified by   Dr. Sharpless in his first year as NCI Director: 
  • Basic Science: Reaffirm our commitment to basic science to drive novel approaches and technologies
  • Workforce Development: Support the cancer research enterprise by focusing on the workforce of cancer investigators
  • Big Data: Increase data aggregation and interpretation to speed our work across the cancer enterprise
  • Clinical Trials: Fully realize the power of clinical trials through innovative design, administration, and analyses
The plan also highlights research progress and accomplishments supported by the NCI; the development of an experimental balloon to screen for Barrett's Esophagus, led by Drs. Sanford Markowitz and Amitabh Chak, was featured on page 22-23 [ Moinova, Sci Transl Med, 2018]. 
Beyond Skin Deep: Understanding Disparities in Dermatology Services
The odds of a black or Hispanic patient visiting an outpatient dermatologist are about half that of a white patient with the same skin condition, according to a new study in  JAMA Dermatology [Tripathi, JAMA Dermatol, 2018] . Patients most likely to receive outpatient dermatologic services in the study were white, educated women. The findings are among several that describe disparities in the use of outpatient dermatology services.

The new study includes nine years of data from 183,054 dermatology patients across the country. Researchers from Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center analyzed the data looking for demographic and socioeconomic patterns associated with use of dermatologic services.

Raghav Tripathi "Patients who were male, uninsured, Midwestern, insured by Medicaid/Medicare, or had a lower income or educational status were least likely to receive outpatient dermatologic care," said the study's first author, Raghav Tripathi, MPH, medical student at Case Western Reserve University School of Medicine. The odds of a man seeking treatment for a dermatologic condition were about two-thirds that of a woman. Across all patients, service utilization increased proportionately with education level and income.

Tripathi, fellow medical student Konrad D. Knusel, and the study's senior author, Jeremy S. Bordeaux, MD, MPH, professor of dermatology at Case Western Reserve University School of Medicine and member of the Case Comprehensive Cancer Center, presented a portion of this work earlier this year at the International Investigative Dermatology Conference in Orlando, Florida.  more>
Brain Tumor Research Conference
Oct 16, 2018 | Tinkham Veale University Center, CWRU
Case CCC logo Drs. Jill S. Barnholtz-Sloan and Justin Lathia, co-leaders of the Case Comprehensive Cancer Center Brain Tumor Initiative, are  hosting a half-day Brain Tumor Research Conference on Tues, Oct 16 from 8a-12p in the Tinkham Veale University Center Ballroom C. This conference will feature speakers from University Hospitals, Cleveland Clinic and Case Western Reserve University. Breakfast will be provided. 

Please send RSVPs to Tuesday Gibson ( 
3rd Annual Cancer Disparities Symposium
Mar 1, 2019 | Tinkham Veale University Center
Disparities Banner
The 3rd Annual Cancer Disparities Symposium will be held Friday, Mar 1, 2019. 

2019 Symposium Highlights
  • Keynote presentations by renowned disparities researchers and community leaders
    • Opening Keynote by Eliseo J. Pérez-Stable, MD, Director of the National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH)
    • Scientific Keynote presentation by Rick Kittles, PhDAssociate Director of Health Equities, Comprehensive Cancer Center; Professor and Director, Division of Health Equities, Department of Population Sciences, City of Hope
  • Oral and Lightning presentations from selected abstracts
  • Poster session highlighting academic research and community programs
  • Networking session
  • All attendee forum
Call for Abstracts

The Case Comprehensive Cancer Center invites multidisciplinary researchers, community agencies and organizations to submit abstracts for presentation at the 3rd Annual Cancer Disparities Symposium. Abstracts will be divided into two tracks: Scientific Research and Community Programs. Meritorious abstracts will be selected for oral presentations. 

Abstracts must be submitted via email ( by 5pm EST on December 4, 2018.

Cancer Center Seminar Series: Leveraging BIG DATA for novel cancer discoveries
Oct 5, 12p | WRB 1-413

Jill Barnholtz-Sloan, PhD Join us Friday, October 5 at 12p in the WRB 1-413 to hear Jill S. Barnholtz-Sloan, PhD, present " "Leveraging BIG DATA for novel cancer discoveries."  This seminar is p resented by the Cancer Prevention, Control and Population Research Program of the Case Comprehensive Cancer Center. 

Dr. Barnholtz-Sloan is multi-disciplinary researcher trained in biostatistics, population genetics and human genetics. Her role in team science has been essential for multiple successful multi-disciplinary research projects. She is the PI of the Ohio Brain Tumor Study (OBTS), which has served as a multi-site tissue source site for The Cancer Genome Atlas (TCGA), and she is the scientific PI of the Central Brain Tumor Registry for the United States (CBTRUS). Hence, she has extensive experience with multi-site, brain tumor, patient recruitment and bio specimen collection, storage, and clinical annotation. She is the Associate Director for Bioinformatics at the Case Comprehensive Cancer Center and the Associate Director for Translational Informatics for the Institute of Computational Biology at Case Western Reserve University (CWRU), where she is responsible for managing Bioinformatics analysis of high throughput "omics" data and implementing and maintaining a translational informatics solution for research. In addition, she is the Director for Research Health Analytics and Informatics at University Hospitals Health System (UHHS), where she helps facilitate access to and analysis of UHHS data for population health. In addition, she is the Director of the Cleveland Center for Health Outcomes Research (CCHOR) with a primary objective of optimizing "big data" for clinical outcomes modeling, including individualized patient predictions that would drive operational and clinical decision making. Therefore, she has extensive experience in hypothesis development, study design and statistical analysis for studies of various phenotypes in humans and animals and analysis of all types of high throughput "omics" data and clinical outcomes. 

Big data comes in many forms leading to many different types of research opportunities for discovery and validation of health related hypotheses. Here, Dr. Barnholtz-Sloan will define big data, discuss what types of big data are available for cancer research, and provide an example of how big data has been used to change how brain tumors are diagnosed worldwide.
Midwest Association of Core Directors Annual Meeting
Oct 24-26, 2018 | Tinkham Veale University Center
Midwest Association of Core Directors Case Western Reserve University (CWRU) School of Medicine and Cleveland Clinic Lerner Research Institute (LRI) is hosting the 9th annual meeting of the Midwest Association of Core Directors, the regional chapter of the Association of Biomolecular Resource Facilities.

Program Highlights
  • Newest Highlights in Shared Resources Technology & Expertise: Introductory ("101-level") and State of the Science level breakout meetings on Genomics, Mass Spec, Imaging, Administration, Drug Discovery, Entrepreneurship, and RNA Sciences.
  • Satellite Workshops: Option to attend a pre and/or post Satellite Workshop, made possible by supporting Platinum Plus Level Sponsors FEI Thermo Fisher and Ilumina.
  • Core Facility Tours: Pre-conference Core Facility Tours of Cleveland Clinic or Case Western University Research Sites.
  • Tour Microsoft HoLoLens Facility: Limited space to sign up for a unique peek at the Microsoft HoLoLens Facility at CWRU! Only 20 people will be able to see this unique 'lens' into medical education using holographic technology.
Who Should Attend?
All members of the research community are encouraged to attend this conference to learn how core facilities can move your science ahead! 

Registration Discount for CWRU SOM Employees
CWRU School of Medicine Office of Research Administration will cover 50% of the registration fee for CWRU SOM employees. Contact Matt DeVries
( for discount code!
Apr 27-28, 2019 | Seattle, WA
Binaytara Foundation
The 2019 Summit on National & Global Cancer Health Disparities (SCHD19) is planned with the goal of creating a momentum to minimize the disparities in cancer care. The summit will feature lectures, discussions and presidential-style debates among leaders across the spectrum of healthcare delivery. It is our hope that this summit will lead us in a direction to help thousands of cancer patients and their families who are still deprived of cutting-edge cancer treatment.

Call for Abstracts
The Binaytara Foundation invites you to submit abstracts  for presentation at the Summit on National and Global Cancer Health Disparities (SCHD19).  All abstracts presented at SCHD19 will be published in  Anticancer Research .  A limited number of travel grants are available to first authors of high scoring abstracts.
NCI Research Specialist Award (R50)
LOI Deadline: Dec 11, 2018
Application Deadline: Jan 11, 2019
NCI R50 The National Cancer Institute has announced the release of the Research Specialist Award (R50), a Workforce Development initiative. These funding opportunity announcements (FOAs) are targeted to non-tenure track laboratory, core and data scientists whose salary is currently supported by NCI-funded grants. 

The NCI R50 Award encourages the development of stable research career opportunities for exceptional scientists who want to pursue research within the context of an existing NCI-funded cancer research program, but not serve as independent investigators. Award recipients receive salary and travel support, which can provide greater autonomy.

Applicants must have an advanced degree (Masters, PhD, DVM, DDS, MD) in an area of biomedical science or biomedical engineering and have demonstrated cancer research accomplishments in their primary discipline. Additional eligibility requirements can be found in the funding opportunity announcements.
NCCN Oncology Research Program
LOI Deadline: Oct 24, 2018
NCCN logo National Comprehensive Cancer Network®  (NCCN® ) is collaborating with Eli Lilly and Company (Lilly) to offer a new opportunity seeking proposals to bridge gaps in care for gastric and gastroesophageal junction (GEJ) cancer patients in the United States. 

The intent of the   Request for Proposals (RFP)    is to encourage US organizations to submit LOIs describing concepts and ideas for developing, implementing and evaluating programs that close clinical practice gaps and improve the quality of care for patients with gastric/GEJ cancer through adherence to evidence-based medicine guidelines, and improved competence and performance of healthcare providers and healthcare systems.
National Institutes of Health Loan Repayment Program
Application Deadline: Nov 15, 2018
NIH Loan Repayment Program Logo NIH is seeking applications and renewals for their Loan Repayment Programs (LRPs). This set of 
programs was established by Congress and designed to recruit and retain highly qualified health professionals into biomedical or biobehavioral research careers. The escalating costs of advanced education and training in medicine and clinical specialties are forcing some scientists to abandon their research careers for higher-paying private industry or private practice careers.
The LRPs counteract that financial pressure by repaying up to $35,000 annually of a researcher's qualified educational debt in return for a commitment to engage in NIH mission-relevant research. Since tomorrow's medical breakthroughs will be made by investigators starting in their research careers today, the LRPs represent an important investment by NIH in the future of health discovery and the wellbeing of the Nation.
2019 DDCF Clinical Scientist Development Award 
Pre-proposal Deadline: Nov 28, 2018
Doris Duke Charitable Foundation Doris Duke Charitable Foundation (DDCF) is accepting applications for the 2019 DDCF Clinical Scientist Development Award (CSDA). This award  provides grants to early-career physician scientists to facilitate their transition to independent clinical research careers.

The CSDA is a highly competitive award with a success rate of 9% for the 2018 competition. Competitive applicants are expected to have research experience and productivity consistent with the rank of Assistant Professor. 
Melanoma Research Foundation
Deadline: Dec 3, 2018
Melanoma Research Foundation logo
The 2018 MRFBC-BMS Young Investigator Translational Immuno-Oncology Team Science Award is offered through the MRF Breakthrough Consortium (MRFBC) and generously funded through a grant by Bristol-Myers Squibb (BMS). This is a two-year team award of up to $150,000 per year ($300,000 total) to encourage young investigators to not only stay engaged in melanoma research focused on immuno-oncology, but to also foster institutional cross-collaborations. 

Medical Student Research Award
Deadline: Nov 6, 2018
The  2019 Medical Student Research Award  application period is now open. The Medical Student Research Award is a one-year, $3,000 grant supporting medical students early in their careers who are conducting clinical or laboratory-based melanoma research. Eligible areas of research can include the prevention, biology or treatment of melanoma and may focus on the study of cutaneous, ocular, mucosal or pediatric melanoma.
Behind The Scenes Cancer Research Lab: Be Well Facebook Live
90.3 WCPN ideastream - Sep 21, 2018
Thank you for joining our Be Well Facebook Live event -- behind the scenes in cancer research with researchers from the Case Comprehensive Cancer Center: Justin Lathia, PhD, Cleveland Clinic Lerner Research Institute; Anant Madabhishi, PhD, Case Western Reserve University Department of Biomedical Engineering; Smitha Krishnamurthi, MD, Cleveland Clinic Taussig Cancer Institute. 
Searching for the roots of brain cancer
Nature - Sep 28, 2018
To estimate your chances of developing brain cancer, take a look in the mirror. If you see an older white man, you are in the group that is at highest risk of this disease...Strong links to environmental factors have been difficult for researchers to pin down. "We have studied a lot of different factors, over many decades, and we've ruled out a lot," says Jill Barnholtz-Sloan, a cancer epidemiologist at Case Western Reserve University and Case Comprehensive Cancer Center in Cleveland, Ohio.
Dr. Pennell on the cost effectiveness of NGS in NSCLC
OncLive - Sep 25, 2018
Nathan A. Pennell, MD, PhD, director, Lung Cancer Medical Oncology Program, Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, discusses the cost-effectiveness of next-generation sequencing (NGS) for patients with metastatic non-small cell lung cancer (NSCLC).
Popular Science - Sep 21, 2018
In new findings published in the journal  MBio a team of researchers from The University of Texas Medical Branch at Galveston and from China successfully used a Zika virus vaccine currently under development to kill  glioblastoma, an extremely aggressive form of brain cancer that kills most patients in less than two years-the same type of cancer that recently killed Senator John McCain. ..." The truth is, if you take out the non-stem cells, which could be as much as 98 percent of the cancer, they can all eventually return," says Andrew Sloan, a neuro-oncologist at Case Western Reserve University School of Medicine and Case Comprehensive Cancer Center...Although purposely injecting someone with a disease as a medical treatment-virotherapy-can seem haphazard and dangerous, researchers have long worked on the development of viruses as cancer-fighting agents. "Using viruses as a form of cancer therapy has potential," says Justin Lathia, a researcher at the Cleveland Clinic Lerner Research Institute and Case Comprehensive Cancer Center who was not involved with the study. "The key advantages are the virus's ability to simultaneously kill tumor cells directly as well as activate the immune system. But a major disadvantage is the ability to control viral replication. These approaches could still have off-target effects," and essentially turn the virus against healthy cells in the body.
Helio/HemOnc Today - Sep 21, 2018
A $4.7 million grant from the NHLBI will support a Cleveland Clinic-led research consortium's effort to develop a better risk-prediction tool for cancer-associated venous thromboembolism.  The 5-year grant will fund research led by  Keith R. McCrae, MD, professor of molecular medicine at Case Western Reserve University and staff physician in the department of hematology and oncology at Cleveland Clinic, and  Alok A. Khorana, MD professor of medicine at Cleveland Clinic Lerner College of Medicine, both of the Case Comprehensive Cancer Center.
Research sites for the project include Cleveland Clinic's Taussig Cancer Institute and Lerner Research Institute, as well as Beth Israel Deaconess Medical Center at Harvard Medical School and University of Cincinnati.
NIH BULLETIN- Notices and Funding Opportunities
Notice to Extend the Expiration Date for PAR-18-139 "Innovative Questions in Symptom Science and Genomics (R01 Clinical Trial Optional)"(NOT-NR-18-018)

Notice to Extend the Expiration Date for PA-18-157 "Innovative Questions in Symptom Science and Genomics (R21 Clinical Trial Optional)"(NOT-NR-18-019)

Notice to Extend the Expiration Date for PA-18-140 "Applying Metabolomics to Drive Biomarker Discovery in Symptom Science (R01 Clinical Trial Optional)"(NOT-NR-18-020)

Notice to Extend the Expiration Date for PAR-18-158 "Applying Metabolomics to Drive Biomarker Discovery in Symptom Science (R21 Clinical Trial Optional)"(NOT-NR-18-021)

Requests for Applications
Predoctoral Training in Advanced Data Analytics for Behavioral and Social Sciences Research (BSSR) - Institutional Research Training Program [T32](RFA-OD-19-011)
Deadline: May 25, 2019

Program Announcements
Strengthen NCI-Supported Community Outreach Capacity through Community Health Educators of the National Outreach Network (Admin Suppl - Clinical Trial Not Allowed)(PAR-18-931)
Deadline: Dec 15, 2018

Administrative Supplements to Cancer Center Support Grants to Strengthen the Research, Training, and Outreach Capacity of the Geographic Management of Cancer Health Disparities Program (Admin Suppl - Clinical Trial Not Allowed)(PA-18-934)
Deadline: Dec 17, 2018

NIH Administrative Supplements to Recover Losses Due to Hurricanes Harvey, Irma, and Maria Under the Bipartisan Budget Act of 2018 Non-Construction (Admin Supp Clinical Trial Optional)(PA-18-936)
Deadline: Dec 14, 2018

Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)(PA-18-943)
Deadline: Standard dates apply

Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)(PA-18-944)
Deadline: Standard dates apply

Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional)(PA-18-945)
Deadline: Standard dates apply

Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R21 Clinical Trial Optional)(PA-18-946)
Deadline: Standard dates apply

Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)(PAR-18-947)
Deadline: Nov 28, 2018; Mar 14, 2019; Jul 11, 2019; Nov 7, 2019; Mar 11, 2020; Jul 9, 2020; Nov 9, 2020; Mar 15, 2021; Jul 11, 2021
Fri, Oct 5
Developmental Therapeutics Journal Club
8a CA5-120 Cleveland Clinic

Cellular and Molecular Medicine
John Turchi, PhD
Tom & Julia Woof Family Foundation Chair in Lung Cancer Research,  Indiana University
"Drugging the DNA damage response: Novel targets and therapeutic strategies"
10a NC1-202

Pathology Lecture
Elias Haddad, PhD
Professor; Director, MD/PhD Program, Division of Infectious Diseases and HIV Medicine, Drexel University
"Boosting Tfh differentiation by ADA-1 in HIV vaccine development"
10a, WRB 6-136

Cancer Center Seminar Series
Jill Barnholtz-Sloan, PhD
Associate Director for Bioinformatics/Translational Informatics
Sally S. Morley Designated Professor in Brain Tumor Research,  Case Comprehensive Cancer Center and Cleveland Institute for Computational Biology
Director, Research Health Analytics and Informatics, University Hospitals Health System (UHHS)
Director, Cleveland Center for Health Outcomes Research (CCHOR), CWRU
"Leveraging BIG DATA for novel cancer discoveries"
12p WRB 1-413
Mon, Oct 8
Tumor Immunology and Immunotherapy
4p WRB 1-422D
Tues, Oct 9
Cancer Center Research in Progress Seminar
3p WRB 3-136
Wed, Oct 10
PRCHN Seminar
Elaine Borawski, PhD
Director, PRCHN, Angela Bowen Williamson Professor of Community Nutrition, CWRU
"Stakeholder engagement and team science approaches to advance research translation through the Cleveland Clinical and Translational Science Collaborative"
12p   B-03 PRCHN Meeting Room
Thurs, Oct 11
Developmental Therapeutics Journal Club
9a R4-013 Cleveland Clinic

Molecular Biology and Microbiology Seminar
Nga Le and Alex Canfield
Molecular Biology and Microbiology, CWRU
1p SOM W203
Fri, Oct 12
Taussig Cancer Institute Grand Rounds
Jack Khouri, MD
Cleveland Clinic "Daratumumab in Al amyloidosis and multiple myeloma"
8a CA5-120 

Cancer Center Seminar Series Canceled - Homecoming Weekend
12p WRB 1-413
Mon, Oct 15
Cancer Center Research Chalk Talk
Pallavi Tiwari, PhD
Assistant Professor, Biomedical Engineering, CWRU
1p WRB 3-136
Tues, Oct 16
Cancer Impact Lecture
Neil Watkins, MBBS, PhD
Kinghorn Cancer Center
Sydney, Australia
1p NE1-205

Cancer Drug Discovery and Resistance
Babal Jha, PhD
Project Staff, Cancer Biology, Cleveland Clinic
3p WRB 1-422D

Cancer Center Research in Progress Seminar
3p WRB 3-136
Thurs, Oct 18
Developmental Therapeutics Journal Club
9a R4-013
Fri, Oct 19
Taussig Cancer Institute Grand Rounds:  Bruell Lecture
Shirish Gadgeel, MD University of Michigan "Eclectic lung cancer clinical research projects"
8a CA5-120

Cancer Center Seminar Series
Jordan Winter, MD, FACS
Associate Professor, Surgery, CWRU
Chief, Division of Surgical Oncology, UHCMC
Member, GI Cancer Genetics  Program, Case CCC
"Metabolic reprogramming in pancreatic cancer"
12p WRB 1-413

Case Comprehensive Cancer Center 
2103 Cornell Road, Ste 1422
Cleveland, OH 44106-7285